The North America antibody testing market is expected to grow from US$ 3,308.90 million in 2021 to US$ 5,185.67 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028.
The continuously growing burden of chronic diseases on healthcare systems across the world is contributing to the expansion of the antibody testing market in this region. The diagnosis is the first step to any treatment, and test kits are imperative to diagnose any condition to start relevant treatments.
According to the Centers for Disease Control and Prevention (CDC), ~6 in 10 people suffered from at least one chronic disease in the US in 2019. As a result of the growing incidence of various diseases, the demand for antibody testing kits and consumables is increasing as antibody detection is an essential criterion for the diagnosis of several pathogens. Antigen characterization is also vital for understanding and monitoring immune responses to infectious agents and vaccines.
An increase in the prevalence of autoimmune diseases, such as plaque psoriasis, Addison disease, celiac disease - spree (gluten-sensitive enteropathy), dermatomyositis, Graves' disease, Hashimoto thyroiditis, multiple sclerosis, myasthenia gravis, and pernicious anemia is also contributing to the antibody testing market growth in North America. According to the autoimmune report of the International Autoimmune Institute & Bingham Memorial Center for Functional Medicine is recognized as a significant health crisis in the US. 50 million Americans—80% of whom are women—suffer one or more autoimmune conditions. According to a recent NCBI report, the epidemiology analysis of two common autoimmune diseases—systemic lupus erythematosus (SLE) and Sjögren's syndrome—the US has higher prevalence rates than other countries. Thus, rise in the prevalence of diseases and need for early diagnosis for the treatment have compelled manufacturers to launch novel diagnostic kits to cater to unmet demands.
With the new features and technologies, vendors in the North America antibody testing market can attract new customers and expand their footprints in emerging markets.This factor is likely to drive the North America antibody testing market at a promising CAGR during the forecast period.
North America Antibody Testing Market Revenue and Forecast to 2028 (US$ Million)
The North America antibody testing market is segmented into products, indication, and end User. Based on product, the market has been categorized as kits, chemicals and reagents, and consumables. The kits segment accounted for the largest market share in 2020. Based on indication, the North America antibody testing market is segmented into infectious diseases, endocrine diseases, oncology, pregnancy, cardiovascular diseases, autoimmune diseases, and others. In 2020, the infectious diseases segment accounted for the largest market share. Based on end user, the North America antibody testing market is segmented into diagnostic laboratories, hospitals, biopharmaceutical companies, and academic and research institutes. In 2020, the diagnostic laboratories accounted for the largest market share. Based on country, the North America antibody testing market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2020.
Abbott; Abcam plc; Agilent Technologies, Inc.; BD; BIO-RAD LABORATORIES INC.; DiaSorin S.p.A.; F. HOFFMANN-LA ROCHE LTD.; THERMO FISHER SCIENTIFIC INC.; Trinity Biotech; and ZEUS Scientific are among the leading companies in the North America antibody testing market.